Chemical Compound Review:
Prinomastat (3R)-N-hydroxy-2,2-dimethyl- 4-(4-pyridin-4...
Synonyms:
CHEMBL75094, AG-E-40511, AG-3354, AG-3362, AC1LAD25, ...
Hande,
Collier,
Paradiso,
Stuart-Smith,
Dixon,
Clendeninn,
Yeun,
Alberti,
Binger,
Wilding,
Bissett,
O'Byrne,
von Pawel,
Gatzemeier,
Price,
Nicolson,
Mercier,
Mazabel,
Penning,
Zhang,
Collier,
Shepherd,
Shalinsky,
Brekken,
Zou,
Bloom,
McDermott,
Zook,
Varki,
Appelt,
Shalinsky,
Brekken,
Zou,
Kolis,
Wood,
Webber,
Appelt,
Baluk,
Raymond,
Ator,
Coussens,
McDonald,
Caughey,
Foda,
Rollo,
Drews,
Conner,
Appelt,
Shalinsky,
Zucker,
Nakaji,
Ihara,
Takahashi,
Itohara,
Noda,
Takahashi,
Tomimoto,
Shalinsky,
Brekken,
Zou,
McDermott,
Forsyth,
Edwards,
Margosiak,
Bender,
Truitt,
Wood,
Varki,
Appelt,
Behrendt,
Ruiz,
Heath,
Burtness,
Kleinberg,
Salem,
Yang,
Heitmiller,
Canto,
Knisely,
Topazian,
Montgomery,
Tsottles,
Pithavala,
Rohmiller,
Collier,
Forastiere,
- Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. Bissett, D., O'Byrne, K.J., von Pawel, J., Gatzemeier, U., Price, A., Nicolson, M., Mercier, R., Mazabel, E., Penning, C., Zhang, M.H., Collier, M.A., Shepherd, F.A. J. Clin. Oncol. (2005)
- Stromal matrix metalloproteinase-9 regulates the vascular architecture in neuroblastoma by promoting pericyte recruitment. Chantrain, C.F., Shimada, H., Jodele, S., Groshen, S., Ye, W., Shalinsky, D.R., Werb, Z., Coussens, L.M., DeClerck, Y.A. Cancer Res. (2004)
- The matrix metalloproteinase inhibitor prinomastat enhances photodynamic therapy responsiveness in a mouse tumor model. Ferrario, A., Chantrain, C.F., von Tiehl, K., Buckley, S., Rucker, N., Shalinsky, D.R., Shimada, H., DeClerck, Y.A., Gomer, C.J. Cancer Res. (2004)
- Marked inhibition of tumor growth in a malignant glioma tumor model by a novel synthetic matrix metalloproteinase inhibitor AG3340. Price, A., Shi, Q., Morris, D., Wilcox, M.E., Brasher, P.M., Rewcastle, N.B., Shalinsky, D., Zou, H., Appelt, K., Johnston, R.N., Yong, V.W., Edwards, D., Forsyth, P. Clin. Cancer Res. (1999)
- Early combined treatment with carboplatin and the MMP inhibitor, prinomastat, prolongs survival and reduces systemic metastasis in an aggressive orthotopic lung cancer model. Liu, J., Tsao, M.S., Pagura, M., Shalinsky, D.R., Khoka, R., Fata, J., Johnston, M.R. Lung Cancer (2003)
- HIV-1 Tat neurotoxicity is prevented by matrix metalloproteinase inhibitors. Johnston, J.B., Zhang, K., Silva, C., Shalinsky, D.R., Conant, K., Ni, W., Corbett, D., Yong, V.W., Power, C. Ann. Neurol. (2001)
- Inhibition of membrane type-1 matrix metalloproteinase by cancer drugs interferes with the homing of diabetogenic T cells into the pancreas. Savinov, A.Y., Rozanov, D.V., Golubkov, V.S., Wong, F.S., Strongin, A.Y. J. Biol. Chem. (2005)
- Matrix metalloproteinases and matrix metalloproteinase inhibitors in lung cancer. Bonomi, P. Semin. Oncol. (2002)
- Phase I and pharmacokinetic study of prinomastat, a matrix metalloprotease inhibitor. Hande, K.R., Collier, M., Paradiso, L., Stuart-Smith, J., Dixon, M., Clendeninn, N., Yeun, G., Alberti, D., Binger, K., Wilding, G. Clin. Cancer Res. (2004)
- Prinomastat, a hydroxamate inhibitor of matrix metalloproteinases, has a complex effect on migration of breast carcinoma cells. Deryugina, E.I., Ratnikov, B.I., Strongin, A.Y. Int. J. Cancer (2003)
- Venous thromboembolism among patients with advanced lung cancer randomized to prinomastat or placebo, plus chemotherapy. Behrendt, C.E., Ruiz, R.B. Thromb. Haemost. (2003)
- Broad antitumor and antiangiogenic activities of AG3340, a potent and selective MMP inhibitor undergoing advanced oncology clinical trials. Shalinsky, D.R., Brekken, J., Zou, H., McDermott, C.D., Forsyth, P., Edwards, D., Margosiak, S., Bender, S., Truitt, G., Wood, A., Varki, N.M., Appelt, K. Ann. N. Y. Acad. Sci. (1999)
- Phase II, parallel-design study of preoperative combined modality therapy and the matrix metalloprotease (mmp) inhibitor prinomastat in patients with esophageal adenocarcinoma. Heath, E.I., Burtness, B.A., Kleinberg, L., Salem, R.R., Yang, S.C., Heitmiller, R.F., Canto, M.I., Knisely, J.P., Topazian, M., Montgomery, E., Tsottles, N., Pithavala, Y., Rohmiller, B., Collier, M., Forastiere, A.A. Investigational new drugs. (2006)
- Evaluation of intraocular pharmacokinetics and toxicity of prinomastat (AG3340) in the rabbit. Cheng, L., Rivero, M.E., Garcia, C.R., McDermott, C.D., Keefe, K.S., Wiley, C.A., Soules, K.A., Bergeron-Lynn, G., Vekich, S., Zhang, K., Appelt, K., Freeman, W.R. Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics. (2001)
- Matrix metalloproteinase-2 plays a critical role in the pathogenesis of white matter lesions after chronic cerebral hypoperfusion in rodents. Nakaji, K., Ihara, M., Takahashi, C., Itohara, S., Noda, M., Takahashi, R., Tomimoto, H. Stroke (2006)
- Amber force field implementation, molecular modelling study, synthesis and MMP-1/MMP-2 inhibition profile of (R)- and (S)-N-hydroxy-2-(N-isopropoxybiphenyl-4-ylsulfonamido)-3-methylbutanamides. Tuccinardi, T., Martinelli, A., Nuti, E., Carelli, P., Balzano, F., Uccello-Barretta, G., Murphy, G., Rossello, A. Bioorg. Med. Chem. (2006)
- Matrix metalloproteinase-2 and -9 expression increases in Mycoplasma-infected airways but is not required for microvascular remodeling. Baluk, P., Raymond, W.W., Ator, E., Coussens, L.M., McDonald, D.M., Caughey, G.H. Am. J. Physiol. Lung Cell Mol. Physiol. (2004)
- Pharmacologic and Genetic Manipulation of MMP-2 and -9 Affects Retinal Neovascularization in Rodent Models of OIR. Barnett, J.M., McCollum, G.W., Fowler, J.A., Duan, J.J., Kay, J.D., Liu, R.Q., Bingaman, D.P., Penn, J.S. Invest. Ophthalmol. Vis. Sci. (2007)
- Ventilator-induced lung injury upregulates and activates gelatinases and EMMPRIN: attenuation by the synthetic matrix metalloproteinase inhibitor, Prinomastat (AG3340). Foda, H.D., Rollo, E.E., Drews, M., Conner, C., Appelt, K., Shalinsky, D.R., Zucker, S. Am. J. Respir. Cell Mol. Biol. (2001)
- Antitumor efficacy of AG3340 associated with maintenance of minimum effective plasma concentrations and not total daily dose, exposure or peak plasma concentrations. Shalinsky, D.R., Brekken, J., Zou, H., Kolis, S., Wood, A., Webber, S., Appelt, K. Investigational new drugs. (1998)
- Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non-small cell lung cancer tumors: single agent and combination chemotherapy studies. Shalinsky, D.R., Brekken, J., Zou, H., Bloom, L.A., McDermott, C.D., Zook, S., Varki, N.M., Appelt, K. Clin. Cancer Res. (1999)